Joaquin Duato, the CEO and Chairman of the Board of $JNJ, sold 51,218 shares of the company on 01-26-2026 for an estimated $11,318,460. We received data on the trade from a recent SEC filing. This was a sale of approximately 39.1% of their shares of this class of stock. Following this trade, they now own 79,634 shares of this class of $JNJ stock.
$JNJ Insider Trading Activity
$JNJ insiders have traded $JNJ stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOAQUIN DUATO (CEO and Chairman of the Board) has made 0 purchases and 3 sales selling 225,824 shares for an estimated $44,671,548.
- JENNIFER L TAUBERT (EVP, WWC. Innovative Medicine) sold 56,471 shares for an estimated $10,040,882
- JOHN C REED (EVP, Innovative Medicine, R&D) sold 21,721 shares for an estimated $4,185,793
- JOSEPH J WOLK (Exec VP, CFO) sold 16,820 shares for an estimated $2,975,570
- JOHN G MORIKIS purchased 1,250 shares for an estimated $257,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$JNJ Hedge Fund Activity
We have seen 1,885 institutional investors add shares of $JNJ stock to their portfolio, and 1,978 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 12,124,049 shares (+61.6%) to their portfolio in Q3 2025, for an estimated $2,248,041,165
- GQG PARTNERS LLC added 5,988,242 shares (+12137.4%) to their portfolio in Q3 2025, for an estimated $1,110,339,831
- GEODE CAPITAL MANAGEMENT, LLC removed 4,394,021 shares (-7.2%) from their portfolio in Q3 2025, for an estimated $814,739,373
- BLACKROCK, INC. added 3,411,739 shares (+1.7%) to their portfolio in Q3 2025, for an estimated $632,604,645
- FLOSSBACH VON STORCH SE removed 3,347,823 shares (-52.8%) from their portfolio in Q3 2025, for an estimated $620,753,340
- CAPITAL INTERNATIONAL INVESTORS added 3,266,354 shares (+545.6%) to their portfolio in Q3 2025, for an estimated $605,647,358
- ASSENAGON ASSET MANAGEMENT S.A. removed 3,071,786 shares (-69.2%) from their portfolio in Q4 2025, for an estimated $635,706,112
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$JNJ Revenue
$JNJ had revenues of $24.6B in Q4 2025. This is an increase of 9.08% from the same period in the prior year.
You can track JNJ financials on Quiver Quantitative's JNJ stock page.
$JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 15 times in the past 6 months. Of those trades, 4 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 12/18, 11/13, 08/14.
- REPRESENTATIVE LLOYD DOGGETT purchased up to $15,000 on 12/09.
- REPRESENTATIVE THOMAS H. KEAN, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $100,000 on 11/20, 07/31.
- REPRESENTATIVE RICHARD MCCORMICK purchased up to $15,000 on 11/05.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 10/30, 08/04 and 2 sales worth up to $30,000 on 10/31, 10/30.
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 10/10.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE KELLY MORRISON sold up to $15,000 on 08/19.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/28/2026
- TD Cowen issued a "Buy" rating on 01/22/2026
- Goldman Sachs issued a "Buy" rating on 12/19/2025
- Guggenheim issued a "Buy" rating on 12/05/2025
- UBS issued a "Buy" rating on 10/14/2025
- Citigroup issued a "Buy" rating on 10/07/2025
- Wells Fargo issued a "Overweight" rating on 10/03/2025
To track analyst ratings and price targets for $JNJ, check out Quiver Quantitative's $JNJ forecast page.
$JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 16 analysts offer price targets for $JNJ in the last 6 months, with a median target of $225.5.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $262.0 on 01/28/2026
- Ilya Zubkov from Freedom Capital Markets set a target price of $220.0 on 01/27/2026
- Vamil Divan from Guggenheim set a target price of $240.0 on 01/23/2026
- Rick Wise from Stifel set a target price of $220.0 on 01/22/2026
- Joanne Wuensch from Citigroup set a target price of $250.0 on 01/22/2026
- Tim Anderson from B of A Securities set a target price of $221.0 on 01/22/2026
- Louise Chen from Scotiabank set a target price of $265.0 on 01/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
